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The CD34 antigen is a 115 KD surface glycoprotein present on primitive stem cells that has been widely  
employed as a marker for hematopoietic progenitors that are capable of reconstituting bone marrow (1). 
CD34-specific antibodies have recently become available and are an important tool in the study of CD34 
function. The choice of cells that are CD34+ (positive) is important for transplantation; however, the subsequent 
identification of cells with no CD34 marker (negative)  has contradicted the only sole potential of CD34+ 
(positive) cells in successful reconstitution of bone marrow (2). Although recent studies have documented 
the ability of CD34- (negative) cells to confer rapid engraftment with fewer risks of malignancy relapses, a 
large number of clinicians still prefer to use CD34+ (positive) cells for transplantation (3). 
Although the utility of CD34 as a selection marker has been well established, little effort has been made to 
determine its precise role in the hematopoietic microenvironment. We have engineered CD34 expression 
on the cell surface of human HSCs and studied its effects in modulating homing and engraftment behaviors. 
We have systematically performed a structure/function analysis of the CD34 protein using computational 
techniques to  identify critical amino acids necessary for CD34 function and created site-directed mutations 
in these critical residues in order to determine their functional significance in vivo. 
The human CD34 protein sequence we used was from the National Center for Biotechnology Information 
(http://www.ncbi.nlm.nih.gov/)  Entrez  database.  Using  various  in  silico  tools,  we  identified  possible 
functional/ structural homologs that we used to identify structural features indicative of protein binding and 
interacting sites, as well as motifs that have implied biological functions. The most significant among them 
was a Src homology 2/3 (SH2/3) domain, which enables binding to the cytoplasmic adapter  protein Crk-L, 
a protein that mediates downstream signaling relevant to adhesion (4). Several  other potential sites for 
critical interactions in downstream signaling were identified. These studies motivated us to generate alanine 
substitution mutations via PCR-based site-directed mutagenesis at Ser306 and Tyr318 and to analyze the  
effects of these mutations. 
Native and mutated forms of CD34 transfected into human hematopoietic cells were expressed ectopically  
by doxycycline-mediated induction using the Tet-on system (Fig.1a). Proliferation, the surface expression 
levels of adhesion molecules, and the adhesion affinity of transfected cells to fibronectin and stromal cells 
(both irradiated and non-irradiated to mimic damaged marrow) were evaluated in transfected cell lines. 
The native form of CD34 displayed a two-fold enhancement in adherence to fibronectin relative to the 
control (Fig.1b). Similarly, cells expressing CD34 displayed a two-fold enhancement in cellular adhesion,  
whereas  cells  expressing  CD34Ser306  showed  no  enhancement  in  adhesion  compared  to  the  control. 
Cellular adhesion is dependent upon surface adhesion molecules such as ICAM-1, integrin-  β 1, integrin-
αL,  integrin-α5  and  integrin-β 2;  however,  there  were  no  changes  in  the  expression  levels  of  these 
molecules as assayed by flow cytometry. There was also no effect on cellular proliferation as assayed by  
MTT assay. These observations suggest an essential role for CD34Ser306. Enhanced adhesion by native 
CD34  and  mutant  CD34Tyr318  appears  to  involve  high  affinity/avidity  binding  states  in  the  surface 
adhesion molecules. 
In conclusion, the change in binding affinity of hematopoietic cells to both fibronectin and bone marrow 
stromal cells monolayer in culture were significant (Fig.1c). In addition, their binding, even to deteriorated 
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stroma exposed to ionizing radiation, seems to be additive. These observations suggest that HSC CD34 
induces  signaling  and  that  its  overexpression  increases  binding,  overcoming  the  rate  limiting  binding 
affinity necessary for HSC retention in the bone marrow extra-vascular space.  These studies suggest that 
CD34+ cells  have efficient homing/engraftment capabilities that may dramatically reduce the number of 
cells required for clinical hematopoietic stem cell transplantation.
 
Figure.1 (a)
Figure1(b)
Figure.1(c)
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Figure 1 (a-c). Modulation of hematopoietic cells adhesion by CD34 expression  (A) The human CD34 
gene  was  cloned  into  a  tightly  regulated  inducible  mammalian  expression  vector.  In  addition,  two 
substitution mutants corresponding  to Ser306Ala  and Tyr318Ala located in the CD34 cytoplasmic tail  
region were generated. Expression of these mutants in hematopoietic cells showed significant enhancement 
of HSC binding to both fibronectin-coated surfaces (B) and human bone marrow stromal cell layer (C).
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